Searching the Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Critical-size bone defects, which require large-volume tissue reconstruction, remain a clinical challenge. Bone engineering has the potential to provide new treatment concepts, yet clinical translation requires anatomically and physiologically relevant preclinical models. The ovine critical-size long-bone defect model has been validated in numerous studies as a preclinical tool for evaluating both conventional and novel bone-engineering concepts. With sufficient training and experience in large-animal studies, it is a technically feasible procedure with a high level of reproducibility when appropriate preoperative and postoperative management protocols are followed. The model can be established by following a procedure that includes the following stages: (i) preoperative planning and preparation, (ii) the surgical approach, (iii) postoperative management, and (iv) postmortem analysis. Using this model, full results for peer-reviewed publication can be attained within 2 years. In this protocol, we comprehensively describe how to establish proficiency using the preclinical model for the evaluation of a range of bone defect reconstruction options.
Pubmed ID: 32060491
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This polyclonal targets vWF
View all literature mentionsThis polyclonal targets Collagen I
View all literature mentionsThis monoclonal targets Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human Alkaline Phosphatase, Tissue Non-Specific aa 1-100.
View all literature mentionsThis polyclonal targets Human PECAM1
View all literature mentionsThis polyclonal targets CD68 antibody
View all literature mentionsThis monoclonal targets BMP-2/4 (H-1)
View all literature mentionsThis unknown targets Amino terminus of VEGF of human origin
View all literature mentionsThis monoclonal targets Osteocalcin antibody [OC4-30]
View all literature mentions